Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer

Authors: Nagel, Sylke¹; Califano, Raffaele²; Thatcher, Nicholas³; Blackhall, Fiona

Source: Expert Opinion on Pharmacotherapy, Volume 8, Number 18, December 2007 , pp. 3265-3275(11)

Buy & download fulltext article:

Price: $99.00 plus tax (Refund Policy)

Abstract:

The universally accepted first-line treatment for advanced (stage IIIB effusion/IV) non-small-cell lung cancer in patients with a good performance status is a platinum drug in combination with one of gemcitabine, paclitaxel, vinorelbine or docetaxel. Although cisplatin is generally the favoured platinum agent, gemcitabine partnered with carboplatin is convenient to administer and has a favourable toxicity profile. Here, the pharmacology, preclinical and clinical data to support the use of this regimen for the treatment of advanced non-small-cell lung cancer is evaluated.

Keywords: carboplatin; chemotherapy; gemcitabine; non-small-cell lung cancer

Document Type: Drug Evaluation

DOI: http://dx.doi.org/10.1517/14656566.8.18.3265

Affiliations: 1: 1Martha-Maria Hospital, Roentgenstr.1 06120 Halle, Germany 2: 2SC Oncologia Medica, Ospedale Santa Maria della Misericordia, 06156 Perugia, Italy 3: 3Christie Hospital, Department of Medical Oncology, Wilmslow Road, Manchester, M20 4BX, UK

Publication date: 2007-12-01

More about this publication?